3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
2
Gynecologic
2
Genitourinary
2
Gastrointestinal
2
Breast
2
Thoracic
1
NET
1
Lymphoid
1
Head & Neck
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Neoplasms
2
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Multiple Endocrine Neoplasia Type 2a
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Diseases
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Bronchogenic
1
Bronchial Neoplasms
1
Breast Neoplasms
1
Interventions
Fluorodeoxyglucose F18
3
Doxorubicin
3
Cyclophosphamide
3
surufatinib
2
fludarabine
2
entrectinib
2
Radiotherapy
2
Nivolumab
2
Ifosfamide
2
Filgrastim
2
Drug Therapy
2
Cisplatin
2
tivozanib
1
tislelizumab
1
tipifarnib
1
selpercatinib
1
romidepsin
1
repotrectinib
1
regorafenib
1
pembrolizumab
1
milademetan
1
ganitumab
1
fludarabine phosphate
1
entinostat
1
dostarlimab
1
conatumumab
1
cixutumumab
1
cabozantinib
1
atezolizumab
1
alectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
alectinib
×
Endocrine
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts